- Editor's PickNicole Sinclair•2 days ago
On Monday, Medivation (MDVN), which owns Xtandi, confirmed it was being acquired by Pfizer (PFE) for $14 billion. This comes just months after Sanofi (SNY) approached Medivation in a hostile deal, going public with its offer and beginning a process to replace the company’s board. Sanofi lost out on its bid to Pfizer, which was willing to pay up and fold Medivation into its oncology franchise.
- Editor's PickKathy Cherpelis•2 days ago
Medivation (MDVN) stock surged this morning. The cancer drug maker is being bought by Pfizer (PFE) in a deal valued at about $14 billion. The deal is expected to close by the end of the year and will give Pfizer access to Medivation’s cancer drug pipeline.
Medivation, Inc. (MDVN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||80.27 x 200|
|Ask||80.35 x 500|
|Day's Range||80.26 - 80.50|
|52wk Range||26.41 - 80.67|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-74.26|
|Avg Vol (3m)||3,025,346|
|Dividend & Yield||N/A (N/A)|